Sunday, October 06, 2024 9:15:38 PM
I see, thanks for explaining it to me. Sometimes i’m a little slow.
RevImmune is also a coinventor on a patent (nwbo, ucla, revimmune, and the former nwbo CDMO that CRL acquired - having a senior moment trying to remember the name) and it may be the original combination treatment patent, but I could be mistaken.
I believe LP is directly associated with nwbo, advent, revimmune, and more! One of the companies LP is assovisted with added Dr Liau to their Scientific Advisory Panel I think, and I believe Bigger Capital has a large position in it.
I rely too much on memory and my retention and recall isn’t what it used to be. If I weren’t so lazy I would diagram all this stuff out and collect it in a file or database. But since I’m only invested in the nwbo part of LP’s world I figure I can get away with being lazy and I am strictly buy side for the duration with the exception of about 10% for personal family needs that I will need to sell, letting the rest ride and fulfill the greater potential.
The disclaimer: this is not investment advice
RevImmune is also a coinventor on a patent (nwbo, ucla, revimmune, and the former nwbo CDMO that CRL acquired - having a senior moment trying to remember the name) and it may be the original combination treatment patent, but I could be mistaken.
I believe LP is directly associated with nwbo, advent, revimmune, and more! One of the companies LP is assovisted with added Dr Liau to their Scientific Advisory Panel I think, and I believe Bigger Capital has a large position in it.
I rely too much on memory and my retention and recall isn’t what it used to be. If I weren’t so lazy I would diagram all this stuff out and collect it in a file or database. But since I’m only invested in the nwbo part of LP’s world I figure I can get away with being lazy and I am strictly buy side for the duration with the exception of about 10% for personal family needs that I will need to sell, letting the rest ride and fulfill the greater potential.
The disclaimer: this is not investment advice
Recent NWBO News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/26/2025 05:15:34 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
